- Home
- TRUG vs UBX Comparison
TRUG vs UBX Comparison
Compare TRUG & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- UBX
- Stock Information
- Founded
- TRUG 1983
- UBX 2009
- Country
- TRUG United States
- UBX United States
- Employees
- TRUG N/A
- UBX N/A
- Industry
- TRUG
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- UBX Health Care
- Exchange
- TRUG NYSE
- UBX Nasdaq
- Market Cap
- TRUG 15.6M
- UBX 16.5M
- IPO Year
- TRUG N/A
- UBX 2018
- Fundamental
- Price
- TRUG $0.57
- UBX $1.73
- Analyst Decision
- TRUG Strong Buy
- UBX Strong Buy
- Analyst Count
- TRUG 1
- UBX 2
- Target Price
- TRUG $2.00
- UBX $7.00
- AVG Volume (30 Days)
- TRUG 5.3M
- UBX 303.9K
- Earning Date
- TRUG 02-12-2025
- UBX 11-04-2024
- Dividend Yield
- TRUG N/A
- UBX N/A
- EPS Growth
- TRUG N/A
- UBX N/A
- EPS
- TRUG N/A
- UBX N/A
- Revenue
- TRUG $21,917,131.00
- UBX N/A
- Revenue This Year
- TRUG N/A
- UBX N/A
- Revenue Next Year
- TRUG N/A
- UBX $33.62
- P/E Ratio
- TRUG N/A
- UBX N/A
- Revenue Growth
- TRUG 7.68
- UBX N/A
- 52 Week Low
- TRUG $0.35
- UBX $0.94
- 52 Week High
- TRUG $9.36
- UBX $2.02
- Technical
- Relative Strength Index (RSI)
- TRUG 48.94
- UBX 63.32
- Support Level
- TRUG $0.54
- UBX $1.56
- Resistance Level
- TRUG $0.64
- UBX $1.85
- Average True Range (ATR)
- TRUG 0.12
- UBX 0.22
- MACD
- TRUG -0.01
- UBX 0.05
- Stochastic Oscillator
- TRUG 11.12
- UBX 75.96
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.